Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

hypertrophy/fetma

Länken sparas på Urklipp
Sida 1 från 32 resultat

Use of droloxifene for the treatment of protastic disease, endometriosis and obesity

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates to remedies for prostate diseases, endometriosis and obesity comprising, as active ingredient, droloxifene having the chemical structure represented by the following formula, ##STR1## or a pharmaceutically acceptable salt thereof. BACKGROUND OF THE
CROSS-REFERENCE TO RELATED APPLICATIONS This U.S. patent application is a national stage application under 35 U.S.C. .sctn.371 of international application PCT/ES2013/070309, filed May 16, 2013, and claims the benefit of priority under 35 U.S.C. .sctn.119 of Spanish Patent Application No. 201230796,

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

Regulation of metabolism by miR-378

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: MIRG.sub.--022.sub.--01WO_SeqList_ST25.txt, date recorded:

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto. BACKGROUND OF THE INVENTION The estrogen hormone has a broad spectrum of effects on tissues in

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto. BACKGROUND OF THE INVENTION The estrogen hormone has a broad spectrum of effects on tissues in

Method for regulating size of vascularized normal tissue

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors. BACKGROUND OF THE INVENTION The prevalence

N-benzylindole modulators of PPARG

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents

N-biphenylmethylindole modulators of PPARG

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents

Compounds and methods for modulation of estrogen receptors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods

Cardioprotective phosphonates and malonates

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION This invention relates to pyridoxine phosphonate analogues, to pyridoxine malonate analogues, to their preparation, to pharmaceutical compositions thereof, and to treatments for cardiovascular and related diseases, for example, hypertrophy, hypertension, congestive heart
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge